Table 2.

Clinical Decision Aids Based on Clinical Data Used for Alcoholic Hepatitis Prognostication

Test	Description	Cutoffs	Clinical Use	Advantages	Disadvantages	Guideline Recommended
ABIC score	Age, serum bilirubin, INR, creatinine	Low risk for mortality <6.71 Intermediate risk 6.71-9.0 High risk >9.0	Prognosis	3 risk categories Possible dynamic use at Day 7 for prognostication	Threshold for corticosteroid initiation remains uncertain Only verified in Spain	None
GAHS	Age, BUN, PT/INR, serum bilirubin, WBC	Severe AH ≥9	Initiation of corticosteroids if MDF ≥32 and GAHS ≥9	Improves performance of MDF when severe AH diagnosed (MDF >32)	Only verified in United Kingdom	EASL
Lille model	Age, albumin, serum bilirubin (day 0 and day 7), creatinine, PT	Corticosteroid response <0.45 Nonresponse ≥0.45 (partial response 0.46-0.56)	Response to corticosteroids	3 risk categories Dynamic assessment Early discontinuation of corticosteroids in non-responders.	Partial response creates uncertain clinical decision making	AASLD, ACG, EASL
MDF	INR, serum bilirubin	Severe AH ≥32	Disease severity and initiation of corticosteroids	Decades of use for AH Used by most AH trials	False positives may lead to unnecessary corticosteroid treatment Inferior prediction of mortality beyond 30-days	AASLD, ACG, EASL
MELD score	Creatinine, INR, serum bilirubin, sodium	Severe AH ≥21	Disease severity and prognosis	Decades of use for hepatology and LT	Threshold for corticosteroid initiation remains uncertain	AASLD, ACG

AASLD=American Association for the Study of Liver Diseases; ABIC=Age, serum Bilirubin, INR and Creatinine; ACG=American College of Gastroenterology; AH=alcoholic hepatitis; AUROC=area under the receiver operator curve; BUN=blood urea nitrogen; EASL=European Association for the Study of the Liver; GAHS=Glasgow Alcoholic Hepatitis Score; LT=liver transplant; MDF=Maddrey discriminant function; MELD=Model for end stage liver disease; PT=prothrombin time; WBC=white blood cell